Drug Discovery World

MARCH 24, 2023

dendritic cells, monocytes) triggers a broad immune response that includes significant increases in cytotoxic CD8 plus T cells armed with chemo-induced tumour antigens to target cancer. This synergy was demonstrated by the AIPAC Phase IIb trial’s encouraging efficacy and safety, including a over 2.9-month

Trials 130

Trials Immune Response FDA Clinical Development 130

Drug Discovery World

FEBRUARY 19, 2024

Replicate Bioscience has shared positive results from the Phase I trial of RBI-4000, its srRNA-based rabies vaccine. In this clinical trial, evaluating safety and immunogenicity of RBI-4000 , participants received one or two doses of srRNA vaccine at low doses (0.1mcg, 1mcg or 10mcg).

Vaccine 130

Vaccine Immune Response RNA Virus 130

Drug Discovery World

JANUARY 17, 2023

Genoscience Pharma, a clinical-stage biotech company developing lysosomotropic drug candidates for the treatment of cancer, fibrosis and auto-immune diseases through autophagy modulation has launched the ABE-LIVER study, along with trial sponsor Grenoble University Hospital. . The trial . The primary criteria is PFS.

Clinical Trials 130

Clinical Trials Trials Drug Development Hospitals 130

Drug Discovery World

JANUARY 10, 2023

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for VAX-24, Vaxcyte’s 24-valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. . The post Breakthrough Therapy designation for pneumococcal disease vaccine appeared first on Drug Discovery World (DDW).

Vaccine 130

Vaccine Therapies Disease Immune Response 130

Plenge Gen

APRIL 7, 2020

Pharmacologic intervention has the opportunity to impact disease progression in the SARS-CoV-2 / COVID-19 crisis. Repurposing of approved therapies is the fastest way to impact patients today, as these medicines have regulatory approval to enable investigator-initiated trials and have a manufacturing process to ensure drug supply.

Immune Response 52

Immune Response Disease Clinical Trials Drugs 52

Drug Discovery World

MAY 15, 2024

Researchers have developed a new vaccine technology that can provide protection against a broad range of coronaviruses with potential for future disease outbreaks – including ones we don’t know about yet. The study demonstrated that the new vaccine raises a broad immune response, even in mice that were pre-immunised with SARS-CoV-2.

Vaccine 130

Vaccine Immune Response Clinical Trials Virus 130

The Pharma Data

AUGUST 16, 2021

Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV. “In Induction of innate immunity was investigated via specific cytokine markers.

Immune Response 52

Immune Response Vaccine Virus RNA 52

Drug Discovery World

AUGUST 16, 2022

Known as a bivalent vaccine, Spikevax was approved following data that show it triggers a strong immune response against both Omicron (BA.1) The booster dose was also found to generate a good immune response against the Omicron sub-variants BA.4 1) and the original 2020 strain 1. . References . 1: [link] .

Immune Response 130

Immune Response Vaccine Clinical Trials Virus 130

Drug Discovery World

MARCH 26, 2024

It is approved in adults and adolescents (12 years of age and older weighing at least 40kg) who are moderate-to-severely immune compromised due to certain medical conditions or receipt of certain immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to Covid-19 vaccination.

FDA Approval 130

FDA Approval FDA Clinical Trials Immune Response 130

The Pharma Data

NOVEMBER 10, 2020

Canadian biopharmaceutical company Medicago has announced that its investigational COVID-19 vaccine generated “significant antibody and cellular immune responses” after two doses in all subjects in an early-stage clinical trial. Based on the promising phase 1 data, the company plans to proceed with a phase 2/3 clinical trial. “We

Immune Response 40

Immune Response Vaccine Clinical Trials Virus 40

Drug Discovery World

APRIL 11, 2024

Together with my colleagues, I am tackling what is one of the most pressing problems in biotech, the discovery of targets to serve as the basis for new therapies for cancer and infectious diseases. Beyond infectious diseases, we are expanding our efforts to include anti-cancer therapeutics.

Research 147

Research Immune Response Disease Laboratories 147

Drug Discovery World

MARCH 27, 2023

The first subjects have been dosed in a Phase I clinical trial of VXX-401, an investigational vaccine designed to lower low-density lipoprotein (LDL) cholesterol, a known factor in heart disease. We’re excited to get this first-in-human trial of VXX-401 started.

Vaccine 130

Vaccine Immune Response Trials Clinical Trials 130

Drug Discovery World

OCTOBER 27, 2023

HB-400, a novel arenaviral therapeutic vaccine developed by HOOKIPA Pharma and Gilead Sciences, has been shown to generate robust T cell responses specific to hepatitis B virus with high antibody levels in a preclinical setting. A Phase I clinical trial to evaluate the safety and tolerability of HB‑400 in humans is ongoing.

Vaccine 130

Vaccine Immune Response Virus Clinical Trials 130

Drug Discovery World

JANUARY 3, 2023

A monoclonal antibody to prevent Covid-19 in vulnerable patients, AZD3152, has entered clinical trials less than 12 months after discovery. . The commencement of the trial triggers a $5 million milestone payment to RQ Bio and will enable the company to execute its four scientific programmes focused on viral diseases. .

Immune Response 130

Immune Response Clinical Trials Vaccine Licensing 130

Drug Discovery World

DECEMBER 16, 2022

The investment allows the company to focus on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases. . STC-15 triggers both direct cytotoxic and immune response-based efficacy mechanisms in solid tumour and leukaemia models.

RNA 130

RNA Immune Response Small Molecule Therapies 130

DrugBank

JULY 18, 2024

Vaccines have consistently demonstrated their efficacy in protecting people from infectious diseases. This led to the eradication of smallpox and polio – two debilitating diseases that historically caused global epidemics. Adjuvants are substances added to vaccines to enhance the immune response.

Vaccine 82

Vaccine Immune Response Clinical Trials Virus 82

Drug Discovery World

APRIL 3, 2023

This year, the team will launch a combined Phase I and IIa trial of R805/CX-011 for the treatment of osteoarthritis in patients in collaboration with the start-up Carthronix. The post Potentially ‘regenerative’ osteoarthritis drug moves to clinical trial appeared first on Drug Discovery World (DDW).

Clinical Trials 130

Clinical Trials Trials FDA Approval Drugs 130

Drug Discovery World

APRIL 16, 2023

The clinical benefit was observed regardless of the tumour mutational burden (TMB) status, according to results from the Phase IIb KEYNOTE-942 clinical trial presented at the AACR Annual Meeting 2023, held April 14-19. In addition to encoding the target antigens, mRNA vaccines also provide adjuvant properties that amplify the immune response.

Vaccine 130

Vaccine Immune Response Medical Schools Trials 130

Drug Discovery World

MAY 30, 2024

Dr Pollock is the Chief Investigator of the LEGACY03 clinical trial, a study aiming to investigate lymph nodes and vaccination responses across age groups. RA: Could you tell us about the LEGACY03 trial? As we age, in adult life, changes in immunity, in particular in immune cells, affect how we respond to vaccines.

Vaccine 147

Vaccine Protein Expression Clinical Trials Immune Response 147

Drug Discovery World

JANUARY 18, 2024

Poolbeg Pharma, a biopharmaceutical company focused on the development and commercialisation of medicines targeting diseases with a high unmet medical need, has announced promising in vivo results for POLB 001 in addressing cancer immunotherapy-induced cytokine release syndrome (CRS). million cases of cancer by 2030 1,2.

Treatment 162

Treatment Clinical Trials Immune Response Therapies 162

Drug Discovery World

MAY 23, 2024

The virus is engineered to enter the cancer cells and replicate rapidly, which breaks the cells open and exposes them to the immune system, effectively destroying them. The research team has already used the virus in a small Phase I trial where responses to the treatment were seen in 11 out of 12 children.

Virus 147

Virus Immune Response Vaccine Engineering 147

The Pharma Data

MARCH 31, 2022

A Phase 2 clinical trial evaluating various additional COVID-19 booster shots has begun enrolling adult participants in the United States. The study, known as the COVID-19 Variant Immunologic Landscape (COVAIL) trial, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Clinical Trials 52

Clinical Trials Trials Immune Response Vaccine 52

Drug Discovery World

NOVEMBER 30, 2022

The University of Queensland is set to take a second-generation molecular clamp vaccine to a proof-of-concept human trial. . million to support further development of the re-engineered technology for use in the global response to future disease outbreaks. . Clamp technology .

Vaccine 130

Vaccine Immune Response Virus Engineering 130

Drug Discovery World

FEBRUARY 6, 2023

This is part of why patients in trials and the clinic can experience severe toxicity and adverse events, reject their therapy with an immune response, or completely fail to respond to treatment. These technologies in no way recapitulate the proteome that antibodies are tested against within a single human in nature.

Immune Response 130

Immune Response Clinical Trials Drug Development Production 130

Drug Discovery World

JULY 25, 2023

These include two antibodies for modulating immune responses in cancer and autoimmunity, which are being advanced through pharmaceutical partnerships with Novartis and GlaxoSmithKline. I mean, if you have Hashimoto’s disease, in three weeks your thyroid gland will disappear.

Immune Response 246

Immune Response Therapies Vaccine Production 246

Drug Discovery World

NOVEMBER 8, 2022

mRNA-4157/V940 is currently being evaluated in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with high-risk melanoma in a Phase II clinical trial being conducted by Moderna. . KEYNOTE-942 is an ongoing randomised, open-label Phase II trial that enrolled 157 patients with high-risk melanoma.

Vaccine 130

Vaccine Immune Response Research Laboratories Clinical Trials 130

Drug Target Review

JANUARY 23, 2024

In April 2023, we saw the first randomised data applying an individualised vaccine in combination with checkpoint inhibition for resectable melanoma, demonstrating benefit in terms of time to disease recurrence. Espen integrates clinical and research expertise as Director of Medical Affairs.

Treatment 122

Treatment Immune Response Vaccine Therapies 122

Drug Discovery World

APRIL 16, 2023

The addition of pembrolizumab (Keytruda) to gemcitabine and cisplatin improved overall survival in patients with untreated metastatic or unresectable biliary tract cancer, according to results from the Phase III KEYNOTE-966 clinical trial. The approval was based on results from the TOPAZ-1 clinical trial. months vs. 6.9 months and 5.6

Clinical Trials 130

Clinical Trials Immune Response Trials Therapies 130

The Pharma Data

JULY 18, 2021

Clinical Data Supporting Approval Demonstrated Non-Inferior Immune Responses for the Serotypes Shared with PCV13 (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F). VAXNEUVANCE Elicited Superior Immune Responses for Serotypes 3, 22F and 33F Compared to PCV13, Which Are Major Causes of Disease.

Disease 52

Disease Immune Response Vaccine FDA Approval 52

The Pharma Data

SEPTEMBER 14, 2020

It forms part of the UK Recovery Trial, which found that a cheap steroid called dexamethasone could save lives. Prof Martin Landray from the University of Oxford, who is co-leading the Recovery Trial, said: “This is the first type of treatment that’s targeted for this specific virus. ” How will the trial work?

Trials 52

Trials Immune Response Virus Vaccine 52

The Pharma Data

DECEMBER 8, 2020

8, 2020 — AstraZeneca’s COVID-19 vaccine is safe and effective, new data from late-stage trials shows. Overall, the vaccine protected against symptomatic disease in 70% of cases, according to a team led by researchers from Oxford University in England. TUESDAY, Dec. 8 in The Lancet.

Vaccine 52

Vaccine Trials Immune Response RNA 52

Drug Discovery World

MAY 9, 2023

Fewer than 5% of oncology drugs that enter clinical trials in the US receive US FDA approval. This abysmal success rate significantly trails the overall approval rate for compounds entering human trials (about 10% of which reach commercialisation).

Drug Development 130

Drug Development Clinical Trials Animal Testing Cell Based Assays 130

Drug Discovery World

FEBRUARY 28, 2024

Using IgE to treat cancer In the UK, a Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working. Research into new cancer drugs remain strong.

Drug Development 162

Drug Development Research Clinical Trials Drugs 162

The Pharma Data

APRIL 15, 2022

NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive results from a Phase 2/3 clinical trial evaluating the safety, tolerability and immunogenicity of a 10-µg booster (third) dose of the Pfizer-BioNTech COVID-19 vaccine in healthy children 5 through 11 years of age. About the Phase 1/2/3 Trial in Children. Pfizer Inc.

Immune Response 52

Immune Response Vaccine Clinical Trials Virus 52

Drug Target Review

MARCH 1, 2024

This antigen-spreading is critical to long-term protection because tumour often develop with inconsistent antigen expression – equipping the immune response to target many diverse tumour antigens may allow for more complete anti-tumour activity. Dr Haqq holds multiple patents and publications.

Immune Response 105

Immune Response Vaccine Therapies Small Molecule 105

SugarCone Biotech

JUNE 10, 2024

Targeting 4-1BB remained of interest to the immuno-oncology field as cell culture experiments and tumor models in mice suggested that robust anti-tumor immune responses could be triggered by anti-4-1BB antibody therapies. This is the T cell type most closely associated with anti-tumor immune responses.

Immune Response 88

Immune Response Production Regulations Clinical Trials 88

The Pharma Data

SEPTEMBER 1, 2020

AstraZeneca has started a Phase 3 trial of its experimental coronavirus vaccines in the US, making it the third company to start late-stage trials of a vaccine. . The trial will see participants receive either two doses of the vaccine or a placebo. Photo by Daniel Paquet from Regina, Canada. Conor Kavanagh.

Vaccine 52

Vaccine Trials Immune Response Virus 52